Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Alzheimers Disease Related Dementias (R01 Clinical Trial Not Allowed)
Notice NOT-NS-22-004 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 23, 2021 Category: Research Source Type: funding
CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-21-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce acute effects of chemical threat agents that affect the eyes and lungs. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP). (...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 25, 2021 Category: Research Source Type: funding
Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R21 Clinical Trial Optional)
Funding Opportunity RFA-MH-21-226 from the NIH Guide for Grants and Contracts. Companion to R01 (RFA-MH-21-225). The shock and kill strategy is one of the commonly used approaches for targeting latent reservoirs in hopes to cure HIV-1. It is based on the concept of purposely inducing reactivation of latent reservoirs in ART (antiretroviral therapy)-treated individuals by using stimulatory agents. However, it has become increasingly evident that attempts at elimination of HIV-1 reservoirs through latency reactivating agents (LRA) -mediated reactivation alone may not be sufficient. Novel strategies such as immunotherapy a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 24, 2021 Category: Research Source Type: funding
Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R01 Clinical Trial Optional)
Funding Opportunity RFA-MH-21-225 from the NIH Guide for Grants and Contracts. The shock and kill strategy is one of the commonly used approaches for targeting latent reservoirs in hopes to cure HIV-1. It is based on the concept of purposely inducing reactivation of latent reservoirs in ART (antiretroviral therapy)-treated individuals by using stimulatory agents. However, it has become increasingly evident that attempts at elimination of HIV-1 reservoirs through latency reactivating agents (LRA) -mediated reactivation alone may not be sufficient. Novel strategies such as immunotherapy and gene excision therapies to opti...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 24, 2021 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Funding Opportunity PAR-21-233 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel e...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 23, 2021 Category: Research Source Type: funding
NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-21-209 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to recruit Early Stage Investigators (ESI) to pursue research programs of interest to NIH Chemical Countermeasures Research Program (CCRP) under the Countermeasures Against Chemical Threats (CounterACT) grant/cooperative agreement program. ESI CounterACT R21 projects may be exploratory, applied, proof of principle, or high risk-high impact research to discover safe and effective therapeutics to mitigate toxicities resulting from exposures to highly toxic chemicals. A distinct featur...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 19, 2021 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Funding Opportunity PAR-21-162 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel e...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 29, 2021 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Funding Opportunity PAR-21-163 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel e...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 11, 2021 Category: Research Source Type: funding
Rural Alaska Household Hazardous Waste Backhaul Service Program
A contract with a Tribal government or intertribal consortia to backhaul hazardous waste and other materials from rural Alaskan communities to reduce the toxicity of landfills and emissions from open waste burning. Geographic coverage: Alaska -- Denali Commission, U.S. Environmental Protection Agency (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - March 5, 2021 Category: American Health Source Type: funding
Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)
Funding Opportunity PAR-20-316 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54s). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutica...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 21, 2020 Category: Research Source Type: funding
Application of Artificial Intelligence and Machine Learning for Advancing Environmental Health Sciences (R41 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-21-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When developed and validated, these methodologies or approaches will further advance the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessment...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 10, 2020 Category: Research Source Type: funding
Application of Artificial Intelligence and Machine Learning for Advancing Environmental Health Sciences (R43 Clinical Trial Not Allowed)
Funding Opportunity RFA-ES-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Phase I (R43) SBIR grant applications from small business concerns (SBCs) to develop promising methodologies using Artificial Intelligence (AI) and Machine Learning (ML) approaches to advance environmental health research and decisions. When further developed and validated, these methodologies or approaches should improve the accuracy of toxicity prediction, help in prioritizing chemicals for more relevant or targeted testing, identify and/or fill data or knowledge gaps in toxicity assessme...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 10, 2020 Category: Research Source Type: funding
Presolicitation Notice: Request for Proposals (RFP) 75N91021R00004"Preclinical Toxicology of Large Molecule Drugs Developed for Cancer and Other Indications"
Notice NOT-CA-21-013 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 4, 2020 Category: Research Source Type: funding
Presolicitation Notice: Request for Proposals (RFP) 75N91021R00003 "Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications"
Notice NOT-CA-21-012 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 4, 2020 Category: Research Source Type: funding
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-313 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or preve...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2020 Category: Research Source Type: funding
